Amwell (AMWL) Q2 2022 Earnings Call Transcript

Amwell (AMWL 3.31%)
Q2 2022 Earnings Call
Aug 04, 2022, 5:00 p.m. ET

Contents:

• Prepared Remarks
• Questions and Answers
• Call Participants

Prepared Remarks:

Operator

Good evening. My name is Rex, and I will be your conference operator today. At this time, I would like to welcome everyone to the Amwell 2Q '22 earnings conference call. [Operator instructions] Sue, you may begin your conference.

Sue Dooley -- Investor Relations

Hello, everyone. Welcome to Amwell's conference call to discuss our second fiscal quarter of 2022. This is Sue Dooley of Amwell investor relations. Joining me today are Amwell's chairman and CEO, Dr.

Ido Schoenberg; and Bob Shepardson, our CFO. Earlier today, we distributed a press release detailing our announcement. The release is posted on our website at investors.amwell.com and is also available from normal news sources. The conference call is being webcast live on the investor relations page of our website, where a replay will be archived.

Before we begin our prepared remarks, I'd like to take this opportunity to remind you that during the course of this call, we will make forward-looking statements regarding projected operating results and anticipated market opportunities. This forward-looking information is subject to the risks and uncertainties described in Amwell's filings with the SEC, and actual results or events may differ materially. Except as required by law, we undertake no obligation to update or revise these forward-looking statements. On this call, we'll refer to both GAAP and non-GAAP financial measures.

A reconciliation of GAAP to non-GAAP financial measures is provided in our posted earnings release. With that, I'd like to turn the call over to Ido for his opening remarks. Ido?

Ido Schoenberg -- Chairman and Chief Executive Officer

Thank you, Sue. Q2 was another important quarter for our company as we make progress on the launch of Converge, our technology platform powering the innovative healthcare organizations leading the way to our hybrid care future. We are proceeding according to our plan for the year, and our team is engaged and inspired by a clarity of purpose and well-defined role in a digital-first future. I'll start by reviewing some highlights of the quarter, then I'll take a moment to discuss the market for our solutions and some customer examples.

Bob will then review some key metrics, our financial results and our guidance. Then we'll open the discussion with your questions. To begin, here are a few highlights from Q2. A key workflow in Q2 has been supporting CVS Health on the launch of the virtual care delivery platform they announced in May.

This is a new consumer-centric offering designed to bring together the many elements of CVS Health ecosystem services into a single integrated experience with unified digital front door. The CVS virtual care digital front door is an exciting new initiative. And we are honored to be selected as the backdrop for this vision. I want to take this opportunity to thank the Amwell team members on the front lines of these extraordinary efforts.

Turning to development of Converge. We are making good progress delivering our industry-leading digital care delivery-enablement platform. With CVS well underway and a substantial part of our platform in live deployments, our R&D efforts are focused on bringing Converge over the finish line. We continue to prioritize existing customer migrations.

Demand for our solution continues to grow, and sales conversations are proceeding according to our plan. Active providers on the Amwell platform reached an all-time high this quarter and are 45% higher than a year ago. Visits on Converge remain steady at 9% of total visits through the Amwell platform, which is reasonable and expected as we shift our focus to more complex, sizable Converge customer migrations, which naturally take longer. We expect a healthy growth in Converge visits in the second half of the year.

We continue to add to the Amwell team, putting in place some great additional talent to enhance the clinical dialogue around Converge. Dr. Carrie Nelson joins us as our Chief Medical Officer. Carrie's clinical perspective will be crucial to the continued sales and implementation of our platform in collaboration with our sales and services teams.

Regarding our sales organization and go-to-market efforts, we held our midyear sales meeting in June. Our teams are gearing up to accelerate out of this transitional time, ready to expand with our new infrastructure software solution. We are going to market with a plan for Converge that highlights our well-defined role with messaging that demonstrates the ROI benefits of our future-ready enterprise platform offering that allows clients to select the modules and program they need now and expand when they are ready. And finally, we announced the accelerated integration of SilverCloud Health, our comprehensive behavioral health solution.

This positions us to deliver this compelling solution to the market more quickly, enabling our payer and provider customers to reach more members and patients with best-in-class care, driving substantial cost savings and patient benefits during this time of great need. Now I'd like to take a moment to provide a brief update on Converge development. Converge development is continuing at a rapid pace. We continue to extend and enhance the platform as a stand-alone connective infrastructure powering a seamless and elegant experience.

We are also innovating in real time as we deploy with our customers, creating digital-first best practices that are setting the standard for broader industry utilization. For example, with Converge, we enable an EHR direct invite, which requires no log-ins or passwords and no waiting room for patients. In a single motion, a clinician simply opens an instance within the EHR, text the patient link, conduct the consult and document the visit. In another example of Converge differentiation, we introduced the next-patient feature, which creates a seamless way for providers and payers to connect patients and clinicians with speed and efficiency.

The next-patient capability allows providers to accept the patient without a previous appointment from a queue directly in their EMR or their provider portal, blending clinical networks to increase patient access and maximize revenue. Patients coming in through their provider or health plan portals are automatically matched with the next available provider, creating shorter wait times and an optimal patient experience. With this feature, the benefits accrue to all players. As we complete the build of Converge and with each additional customer migration, we drive an ongoing transformation at our company, from being a healthcare services company to a technology company that enable meaningful transformation of our clients' digital care delivery.

Now I'd like to take a moment to discuss the market and how we plan to pursue growth through a land-and-expand strategy. In my regular discussions with our customers, there is a strong recognition of the pressing need to evolve to a hybrid model of care that blends the physical, virtual and automated modalities in a single digital-first experience. Health care organizations are facing a new world that is challenging for them in many ways. The need for operational efficiency, the staffing crisis and technological fragmentation all combine to create an urgent need to achieve a vision for digital care delivery.

Workflows, priorities and timelines will vary, but the future that seamlessly integrate digital care delivery is certain and plays right into the heart of our value proposition. We believe Converge is the infrastructure to support this emerging model. Converge and our other solutions have been built on years of investing and understanding the current and future needs of our customers. And our focus and clarity of purpose is resonating with them.

As we migrate customers over to Converge, we are engaging in the sales conversations, which demonstrate the ROI benefits of digital-first approach to healthcare that includes various programs and modules that are optimized on Converge. These sales conversations are specific and compelling. Our teams work together with our customers to identify clinical and operational pain points and configure our programs and modules to provide a seamless digital extension to their care delivery to define new optimized workflows that are more important in today's environment than ever before. At our sales meeting in June, it was great to be reunited in person with our teams and to experience the energy and depths of talent of our teams.

Our leaders shared stories highlighting the powerful benefits of our solution that are defining the sales dialogue, and I'd like to review a few of them. We are delivering efficiencies that reduce costs and expand our customers' ability to deliver care. For example, St. Luke's University Health Network is leveraging our solution to unify multiple care delivery platforms and deliver care directly from the EHR.

They have expanded their ability to reach thousands of patients with virtual behavioral health services and in-hospital monitoring around the clock. Our solution is also enabling improvements in health equity that enhance patient outcomes with multiple paths of care, including automated programs and coaching. Specifically, SilverCloud Health research has found that up to 80% of users show improvement in their depression or anxiety, and 56% of patients with clinical diagnosis are diagnosed free within three months of commencing care. Our modules and programs also drive better outcomes, which also directly impact the bottom line.

For instance, our dermatology program successfully reduces the wait time to see a specialist from an average of 35 days to less than 24 hours. And Sword Health MSK programs have demonstrated 60% lower rates of surgery intent, lower reported levels of pain and reduced medication consumption by nearly 50%. When a program can address the health concern in a timely manner and return the patient to work with less complication, the value to payers and employers is significant. We are empowering data collection that can inform and validate the benefits of new and efficient workflows.

The Dignity Health digital behavioral health team told us, they aim to make virtual care indistinguishable from in-person care, thanks to insight from the data they are using to demonstrate quality outcomes. With our programs, they were able to drive behavioral health visits up from 300 a month to well over 1,000 per month, allowing Dignity Health to dramatically leverage their providers and extend the benefit of digital care in the behavioral health program. Additionally, our solution empowers and accelerates our customers' urgent need to reduce burnout and retain their teams. Last quarter, we told you how Spectrum Health were saving $1 million per year by lowering ED readmission rates.

Specifically, Spectrum used our technology to create a new transition team that stands between patients and the ED to buffer the demand, to manage care and to allow care providers to spend their times appropriately. This solution is resulting in such a compelling provider experience. The Spectrum team uses the program as the recruiting tool when competing for talent. Our Conversa automated engagement programs increase patient touch points while reducing unnecessary outbound calls to patients by as much as 50% and have demonstrated more than doubling of nurse capacity for postsurgical patients.

Also addressing the crisis in clinician burnout, our automated care programs augment the care team, enabling them to practice at the top of their license. Conversa programs are increasingly being recognized for their important role in the future of digital care. A recent article by authors at the University Hospitals of Cleveland described the benefits of our automated care programs in helping to overcome obstacles to conventional care management outreach. The authors highlighted earlier interventions when problems occur, improved outcomes and stronger trusting relationship between patients and care managers as key benefits.

The patient experience is excellent with Amwell's Conversa programs, with research showing that 97% of patients say our automated programs are important in their care. If you want to experience the power of these solutions firsthand, text Hello to 77877 for several impactful demos. These are some of the examples shared at our sales meeting, and they are great stories to tell out in the field as we are gearing up our teams to sell to new customers and expand within existing ones. Now there is one additional element of differentiation that I want to spend a moment on.

We are delivering a powerful multifold ROI benefits of efficiency and revenue generation with the superior patient and provider experience of our AMG providers. AMG allows us to deliver the benefits of an extended and highly available team without competing with our clients in anyway. When customers choose, we provide much needed bandwidth to help alleviate burnout and solve for critical care team shortages like behavioral health, dermatology or neurology. They can even turn this capability off and prioritize their own providers when they choose.

In fact, as we engage in sales conversations with our customers around their digital care delivery aspirations, we are finding that our history as a service provider is a differentiating advantage for us as a software vendor. Our clinical experience rewards our team the ability to have the clinical sales conversations that will result in new workflows that deliver on the promise of digital-first healthcare. This gives us a powerful seat at the table. To wrap up Q2 highlights, I would like to close by saying that we are evolving our platform to help our customers make the transition from transactional healthcare to continuous healthcare.

Our aim is to empower our customers to achieve important ROI benefits while delivering their organizations into the future of digital healthcare. Before closing, I want to add that I'm proud of the way our teams are executing during our transition year, putting in place the crucial elements of our solution, driving engagement and executing on our mission to define and deliver the fundamental infrastructure enabling the future of healthcare. With that, I want to turn the call to Bob. Bob?

Robert Shepardson -- Chief Financial Officer

Thank you, Ido, and thank you all for joining the call this evening. Tonight, I will highlight some of our key operating metrics, then take you through our 2Q '22 financial results. The number of active providers on our platform is one measure we use to demonstrate the value we deliver to our provider and payer customers. We ended the second quarter with approximately 103,500 total active providers, representing 45% growth compared to a year ago.

Providers employed by customers active on our network grew 48% versus last year. Virtual visits have continued to grow nicely despite much improved access to in-person care, demonstrating the continued acceptance of virtual visits as a standard of care. Total visits were over 1.5 million in the second quarter, representing 19% growth versus last year. Scheduled visits grew 20% year over year and represented 73% of visit volume, about even with the first quarter and up from approximately 30% pre-COVID.

We are making steady progress on Converge development, and the migration of our customers to our new platform is proceeding according to our plan. In Q2, total visits on Converge comprised approximately 9% of total visits, which is in line with our average over the last two quarters. As we have discussed, with our less complicated migrations largely behind us, we are now in process on several more complex migrations with our larger clients. These customers account for a much larger percentage of our visit volume.

And as such, we expect our Converge visit percentage to rise over the coming months as those migrations are completed. And now on to our financial results. Total revenue was $64.5 million, reflecting growth of 7% versus the second quarter of '21. The components of revenue are as follows: subscription revenue grew 10% over a year ago and was $29.6 million, which is fairly flat compared to Q1.

This is in line with our expectations and is reflective of this year as a transition year. Our long-term path to profitability is grounded in our plan to drive high-margin subscription revenue growth at a rate that is faster than that of our overall business over the long run. AMG visit revenue grew 8% year over year to $29.7 million, in keeping with seasonal expectations. Revenue per visit was $81, similar to both last quarter and the year ago period.

Our AMG business is an important differentiator in the market and critical to many of our clients, and we view this offering as an important supporting element of our Converge strategy. Our services and Carepoints' revenue was $5.2 million versus $5.9 million a year ago and $4.8 million last quarter. Services and Carepoints both tend to have their strongest revenues in the fourth quarter, as customers seek to drive engagement and use dedicated funds going into ERF. Turning to profitability.

Gross profit margin was 43%, approximately flat to last quarter and the year ago. Our gross margin can vary quarter to quarter based on mixed dynamics. And we believe as we ramp up Converge deployments, the efficiencies associated with our multi-tenant SaaS-based platform will lift our gross margins. Turning to operating expenses and in support of our Converge strategy, R&D spending was flat to last quarter at $37.1 million.

As we indicated in our annual guidance, as we complete the more intensive development work on the platform, R&D should begin to decline during the second half and start to normalize into next year as our long-term path to profitability describes. Sales and marketing spend declined 12% versus 1Q '22. This step-down is seasonally typical because Q1 is a big marketing quarter for us with important industry conferences, making preparations for our sales meetings and some first-of-the-year ad campaigns on behalf of our clients. Finally, adjusted EBITDA improved to negative $42.8 million from negative $47.1 million last quarter and is in line with our plan and guidance for the year.

Transitioning to balance sheet. We are fortunate to have a substantial cash position, ending the quarter with $630.1 million of cash and short-term investments. Turning to our outlook for 2022. We had a very successful first half of the year.

Development of Converge and migrations are proceeding well. We are gearing up our teams to sell Converge, and customers are pleased with the product and connecting with our vision. They are also facing many challenges, including economic uncertainty, margin pressure and staffing shortages. We believe we have a solution to specifically address many of these challenges, making our solution relevant, regardless of the environment.

And we can help them evolve their organizations through this time and beyond to true digital-first healthcare delivery. We enter the back half of this year laser-focused on execution and also realistic about the uncertainties in the broader market environment. We continue to believe that the guidance we provided in February is appropriate, and we are reiterating that guidance today. To summarize, our second quarter was an important and encouraging quarter for us on many fronts.

And we believe we are very much on a path to achieving the broader strategic and financial goals we outlined in February. By putting our technology at the heart of our future, we believe we are on solid ground to execute through this transition year and proceed on a path toward long-term high-margin subscription revenue growth and expanding profitability. With that, I will turn it back to Ido for some closing comments before taking your questions. Ido?

Ido Schoenberg -- Chairman and Chief Executive Officer

Thank you, Bob. We are proud of our team, and we are encouraged by the progress that Q2 represents. In pursuing the strategy to deliver the leading digital care delivery infrastructure, our future is about increasing our mix of high-margin subscription software as we pursue our long-term path to profitability and beyond. Our role in the digital care delivery landscape is clear.

The opportunity in front of us is large and expanding, and we believe we are just getting started. Before we move to Q&A, I wanted to share that soon, we will be publishing our inaugural ESG framework. We are excited for the world to see how we view our company through an ESG lens. With that, operator, would you please open the call for Q&A.

Questions & Answers:

Operator

[Operator instructions] Your first question comes from the line of Charles Rhyee. Your line is open.

Charles Rhyee -- Cowen and Company -- Analyst

Yeah. Thanks for taking the question, and congrats on the quarter. Ido, I wanted to just touch on CVS here. Obviously, you made the announcement in a release at the end of May, obviously, and will get rolled out starting next year.

My understanding is that that's been an ongoing discussion between you and the company. Maybe you can give us a little bit more background on how that kind of conversation started. And sort of what were the things that they were looking for as they are thinking about a virtual care platform. And then lastly, when you guys gave the long-term kind of path to profitability, was that factored already into sort of your thinking at the time? Thanks.

Ido Schoenberg -- Chairman and Chief Executive Officer

Hi, Charles, thank you. As you know, we are very careful to never talk about any of our specific customers, big or small. And CVS is, no doubt, a very important relationship for the company. CVS is a fascinating organization that blends insurance capabilities, retail capabilities, care delivery networks, PBM, population management services and so much more.

We could be more proud and excited about the fact that they chose us as their backlog for their effort, and that effort is very significant. And they alluded to that effort already as late as their recent earnings call. I'm afraid I cannot provide much information beyond what we already shared and was approved by our client. But it is a very, very important undertaking that will be a wonderful demonstration of our new platform and the capabilities.

As far as the path to profitability, this was a generic model. It did not necessarily count specific clients in or out. I'm not sure, Bob, if you have anything else to add to this.

Robert Shepardson -- Chief Financial Officer

I think you covered it, Ido. The guidance that we gave in February contemplated everything we knew at the time. And we had referenced a large booking in the fourth quarter. So yeah, you shouldn't read into the announcement by CVS as something incremental to what our -- what the guidance we gave in February is.

Charles Rhyee -- Cowen and Company -- Analyst

Great. And if I could just follow up, Bob, the guidance you reiterated on the EBITDA guide here. Obviously, you came in better, I think, than expected on the second quarter. Can you give us a little sense on the cadence? And if I recall correctly, you had talked about, as you're ramping up Converge, you're going to be running duplicate platforms.

You outperformed the gross margins. Should we still expect a downtick in the gross margins then in the back half of the year? Thanks.

Robert Shepardson -- Chief Financial Officer

Yeah, Charles, I would say that we do note that the quarter came in better than the consensus for adjusted EBITDA. It is, however, in line with how we thought the year would evolve. The back half, there's a lot going on in terms of getting customers up and running, finishing off the Converge development R&D and kind of across the board in terms of the income statement. So I would stick by the guidance we provided on the -- at least for now, for the adjusted EBITDA and not really think about that different in the context just because of the quarter.

Charles Rhyee -- Cowen and Company -- Analyst

Great. Thank you. Appreciate it.

Robert Shepardson -- Chief Financial Officer

Thank you, Charles.

Operator

Your next question comes from the line of Jack Wallace. Your line is open. Jack, your line is now open.

Jack Wallace -- Guggenheim Partners -- Analyst

Hey, can you hear me?

Robert Shepardson -- Chief Financial Officer

Now, we can.

Jack Wallace -- Guggenheim Partners -- Analyst

Hey, sorry about that. Thanks for taking the questions. It sounds like it was a great quarter, particularly on the expense management side. And I want to piggyback on the following question, you thinking about the cadence of the year.

I think when we were discussing the long-term growth and margin trajectory, the second quarter was called out for being the highest burn, particularly around the R&D line, and that looked like it was flat quarter over quarter. Granted the commentary with some of the large migrations happening in the back half of this year makes sense, but there was also paired with R&D going down over the course of the year. Can you just help us rebucket where the back half of the year expenses look to go? And just within the context of about $90 million of EBITDA burn in the first half of the year, just annualizing that gets you to the high end of your EBITDA guidance. Just trying to figure out where all the moving pieces end up landing.

Thank you.

Robert Shepardson -- Chief Financial Officer

Yeah. I'm not going to go line item by line item and give you the quarterly progression. But I would say that we talked about R&D specifically coming down over the back half of the year. That -- I wouldn't expect that the second quarter represents the high in terms of quarterly spend on R&D.

But we do still stand by the thought that relative to -- on a quarterly basis, we do expect to see some decline in the back half of the year. So whether that comes to pass second half over first half or just fourth quarter over third quarter, I don't want to be too specific around that. But I would tell you that I don't expect that the second quarter is the high quarter for the year on the R&D front, looking at where we are right now. And then gross margins are, right now and in the first quarter, a bit higher than we had talked about in February.

I think we talked about gross margins coming in flattish for the year, given all the puts and takes. And we still stand by that. So I think you'll see some. As visits ramp up over the back half of the year, that has an impact on gross margin.

As services ramp up over the back half of the year, that has an impact on margin. So we will see gross profit margins come in relative to this quarter, which is probably the high for the year. I think that probably covers the largest moving pieces. It's really going to be around R&D, gross margins.

And as we get into the fourth quarter with services and Carepoints ramping up, those are some of the lower-margin products that we offer. And so we'll see that impact as well.

Jack Wallace -- Guggenheim Partners -- Analyst

Gotcha. That's super helpful. I appreciate it. Switching gears here on the Converge front.

You mentioned the Conversa and SilverCloud recently integrated onto the platform. And on the prior call, the first quarter call, there was mention of other key modules that were being converted over -- or being integrated to Converge. What is the status of those other module integrations? And is that happening concurrently with the large customer migrations? Thank you.

Ido Schoenberg -- Chairman and Chief Executive Officer

So Jack, Converge is very much like an operating system. It's a very, very large infrastructure that is designed to host really indefinite number of modules and programs. If you only count Conversa programs, we're looking at more than 150 programs through the cloud has their own slew of programs. We recently announced Sword Health with MSK.

We talked about dermatology, about neurology, telepsychiatry initiatives and many others that really are hard to count and mention over the call. The high-level answer to your question is that we fully expect to add modules that are made in Amwell and growing number of modules that are made by third parties and even our clients to really tie them into this unified infrastructure is so helpful to our clients. Down the road, I would not be surprised if the majority of our modules and programs will not be manufactured by Amwell, but we will just serve as a very large integration layer for all parties, for patients, providers and of course, payers and employers. We don't tend to announce things before they're ready, but you should fully expect more and more diversity, more and more comprehensiveness across the full care continuum on Converge this year and in years to come.

Jack Wallace -- Guggenheim Partners -- Analyst

Gotcha. That's helpful. Thank you so much.

Operator

Your next question comes from the line of Ricky Goldwasser. Your line is now open.

Ricky Goldwasser -- Morgan Stanley -- Analyst

Yeah, hi. Good afternoon, guys. So a couple of questions, but let me start with the first one. So when you think about enterprise clients facing just more challenges now, how is this or is it impacting just the time line of the enterprise sales cycle? And as we think about sort of kind of like selling more, where are you seeing more traction or urgency at health systems versus health plans, who might have stronger balance sheets at the moment?

Ido Schoenberg -- Chairman and Chief Executive Officer

So Ricky, that's a great question. We really see two contradictory trends here. On the one hand, there is no doubt that the macro winds are very clear. People have some serious concerns about the economy.

People are much more careful when they buy, they focus on ROI, and we prepare to have this discussion with existing and new customers. At the same time, it's also very evident, the digital care delivery is proven now more than ever. It's an extremely effective way to improve financial and clinical outcomes and reduce cost. And in many ways, I'm hard press to find a client or even a potential client that doesn't see digital care delivery enablement is a necessary infrastructure they would need in order to survive and compete in this market.

At the same time, we are -- we understand that the ability of people to commit to very large projects upfront really translate into risk that some people are hesitant to make at this time. And this is why we built the Amwell platform, not only Converge, but the combination of Converge, different type of clinical services, strategic services and even hardware in a modular way, so you can buy what you need today and have the peace of mind that you can grow into the future. And that seems to resonate really well in the marketplace. So people can make the necessary investment that they can make with very clear ROI that is super specific to their budget and needs right now this year and look at us as the multiyear, reliable partner as they continue and expand.

It's hard to guess which one of those trends is going to win. But overall, I think the net is net positive. We seem to feel, based on customer feedback, that we have the right offering at the right time, that is somewhat more resilient to market trends than other types of products.

Ricky Goldwasser -- Morgan Stanley -- Analyst

And then another question, and this one is more sort of if we step back. We talked about Converge as a digital care delivery infrastructure. But as we think about sort of the CVS relationship, is the CVS relationship could become more of a blueprint for Converge being, let's say, the digital outright care delivery infrastructure? When I hear kind of like what you talked about, right, you connect the PBM, connect the pharmacy. So you are connecting services that are provided in-person with services they are providing digitally.

Is that a fair way to look at it?

Ido Schoenberg -- Chairman and Chief Executive Officer

Absolutely. Without getting into specifics on CVS, you're absolutely correct that we really see ourselves as an integrator. We make a point not to compete with the different players, especially not with the providers, and really bring them together to create a singular experience. The organizations that really have many of the moving parts would be a terrific example to the capability of the platform.

But even if you have less of the parts and you want to engage, sharing and exchanging information services with other organizations, we don't necessarily compete with you, but really complement your offering and make it better and more sticky, more valuable to your own customers. We really created this tool in order to do that, which is a stark differentiator of Amwell and the Amwell platform versus other players in the market today. This may be your last question, I'm not really sure, but I want to just make the point that I was told recently that this may be one of your last calls, Ricky. So I wanted to express the gratitude of myself and our entire team for many, many years of terrific reviews and analytics and wonderful guidance and wish you the very best on the next chapter in your career.

Ricky Goldwasser -- Morgan Stanley -- Analyst

Very much appreciated, Ido. Thank you.

Operator

Your next question comes from the line of Eric Percher. Your line is now open.

Eric Percher -- Nephron Research -- Analyst

Thank you. Description as an integrator makes an interesting partner for technology companies looking at healthcare. I'd love to hear if there are any updates on the Google relationship. And also your views on Amazon expansion in healthcare, both digital and the care delivery?

Ido Schoenberg -- Chairman and Chief Executive Officer

Hi, Eric. Yes, with Google, I can reiterate what we said recently, they have a cloud service that we trust and we hold some of our activity on. They have some technologies, especially around natural language processing and AI that we are using. We made a very important decision to use our clinical data repository on Google, which opens the way for us to give much better reporting and analytics, which is so important for CIOs as they look at multiple vendors that we bring together and they really want not only one digital door, but they really want one set of oversight into the many ways they touch and engage with the patients.

So we are very pleased with our relationship with Google. But of course, we have other relationships. Cerner is a long-term relationship with Amwell, and now it's part of the Oracle, the other examples. As it relates to Amazon, this is a pretty interesting potential transaction.

In some ways, it's another validation of what we said all along, the technology will transform healthcare. The Oracle example, the Google example, or other data points or reference points. What's really interesting is that Amazon seems to think like us that the right answer is a hybrid model, that brings in-person a new technology, automated, virtual and in-person solutions is the right answer. They also said that they would like to bring care more close to the home.

And Amazon is known for many things. But they're especially known for the logistics and their obsession about the consumer experience, which finally is arriving into healthcare. Eric, you've been on many calls with us. You know that we are equally religious about that, a lot of effort was put in Converge to truly create a phenomenal provider and consumer and really any other type of user experience.

But perhaps most importantly, we see this movement by Amazon as the very strong accelerant to many of our customers, who can use our platform in order to survive and flourish in a marketplace that is becoming incredibly more sophisticated and more competitive to them. Our role as an enabler, our role as an integrator does not hurt anyone, but it could be very, very helpful when they look at their plans to really create an edge for themselves into the future.

Eric Percher -- Nephron Research -- Analyst

That's interesting. And just relative to Oracle and Cerner, is there anything -- any change to the Cerner relationship or any way that your role now is in conflict with what Oracle and -- Cerner has become with Oracle?

Ido Schoenberg -- Chairman and Chief Executive Officer

I really don't think so. Apart from many wonderful relationships really across all levels of both Oracle and Cerner that we maintain. Our recent conversations with both organizations have been very, very positive and really indicate that we are likely to continue and see them as a very good partner of Amwell for many years to come.

Eric Percher -- Nephron Research -- Analyst

Thank you.

Operator

Your next question comes from the line of David Larsen. Your line is now open.

Aron Corin -- BTIG -- Analyst

Hello, this is Aron on for Dave. I just had a quick housekeeping question and then a more general question. First is just with regard to AMG visits in 2Q, I saw the revenue, but I didn't see the visit volume. And then I just want to know how the acquisitions of SilverCloud and Conversa are doing relative to your expectations? I know you didn't break them out, but just curious how they're trending and how you see it going forward?

Robert Shepardson -- Chief Financial Officer

On the AMG visits side, I don't think this is something that we have typically broken out quarter to quarter specifically. I would say it was down a bit seasonally as we talked about kind of in line with revenues. There really wasn't much of a change in revenue per visit quarter over quarter. So you could get to the number pretty easily by just looking at the change in revenues.

It would be around the same level. I hope that's helpful.

Aron Corin -- BTIG -- Analyst

Yeah. Yeah.

Ido Schoenberg -- Chairman and Chief Executive Officer

And as far as the -- thank you for the question about the Conversa and SilverCloud. I would say that those acquisitions were almost existential. They were critical for Amwell. I keep talking about the hybrid of physical and virtual, but we really need a very good technology and capability around the automation, which the strategic positions are more than delivery.

So they've been great as a stand-alone offering. They are even much more powerful under our integrated umbrella. They really change the paradigm in many ways. If you think about automation, it allows the patients to experience healthcare as the companion is always on, something that you can be in touch with the different participants, at the fraction of the cost and has many, many ROI benefit, some of which I shared in my prepared remarks.

Other are available on our website and even with the third parties. So regardless of the exact impact on revenue of specific program, these capabilities, which are now part of the Amwell platform, really allow us to complete everything we have to have in order to end 2022 with a very competitive offering across our entire market. I don't see any other similar need that we are missing for M&A in years to come. So that pretty much covered what we had to acquire, but it was very necessary.

Aron Corin -- BTIG -- Analyst

And just as a follow-up. I think you projected last year that you're going to have about $30 million in revenue for that acquisition. I guess, how is it trending relative to that benchmark for SilverCloud and Conversa.

Robert Shepardson -- Chief Financial Officer

The $30 million, we talked about in the context of really giving some guidance around where those business would be on a stand-alone basis and in the context of an earnout that would run over the course of the year. We, as Ido talked about, opted to accelerate the earnouts and speed the integration of those assets as we saw the value that that could bring us in marketing an integrated offering. And so with that, we're not really looking at these as stand-alone businesses at this point. We're marketing them in packages.

Conversa is offered to customers on the health plan side as you can buy one, two, three, four different Conversa packages along with an amount of visits. And that will determine up and down kind of where you are on your subscription. So it's really -- we're not really thinking about these as stand-alone line items from a revenue perspective anymore because you really just can't break them out in a package sale context. So I would tell you, the businesses are performing as expected.

But more importantly, the strategic value that they bring us and that they have brought us is better than we could have hoped.

Aron Corin -- BTIG -- Analyst

OK. Thank you very much.

Operator

Your next question comes from the line of Stan Berenshteyn. Your line is now open.

Stan Berenshteyn -- Wells Fargo Securities -- Analyst

Hi. Thanks for taking my questions, and I apologize I hopped on late. So if you addressed this, I'm sorry. But we've been hearing just one more news.

So R&D has been a particularly sensitive area in terms of wage inflation pressures. And just as we think about your easing off the gap on R&D spend going into the back half of the year, should we be thinking about any offset or any incremental wage inflation pressures that you're seeing? Any color there would be helpful.

Robert Shepardson -- Chief Financial Officer

Look, I would say that we're seeing pressures on the cost side no different than anybody else. We've really tried to optimize from a staffing perspective by using -- given the nature of the developments of Converge, we have used a lot of outside contractors because as we complete the development of Converge and those discrete projects roll off we're not -- we haven't ramped up headcount and then have to ramp that down. So we've done a lot of contracting externally to get to where we need to be. There has been some pressure from that perspective.

And look, as we are in the market from an FTE perspective as well, we see the wage pressure. That being said, it hasn't put us in a position where I feel like we should be guiding you any differently from an R&D line item perspective going into the second half year. We've, I think, done a good job in dealing on a net basis with our -- with FTEs and again, really leveraging up on the contractor side. So it's there.

We see it, but not to the degree that we would guide any differently.

Stan Berenshteyn -- Wells Fargo Securities -- Analyst

That's helpful. Thank you so much.

Operator

Your final question comes from the line of Jessica Tassan. Your line is now open.

Jessica Tassan -- Piper Sandler -- Analyst

Hi. Thank you so much for taking the questions. I just -- first off, I was hoping you could help us understand what the mix of AMG behavioral versus primary care docs on the platform is roughly? And do you guys feel like you have sufficient capacity within the AMG network at this point to service the virtual primary care contracts you've signed? And also just seasonal demand in -- heading into the back half, like fourth quarter?

Robert Shepardson -- Chief Financial Officer

Yeah, Jess, thanks for the question. We have SLAs across our business and really need to staff AMG appropriately for those SLAs. We're meeting our SLA targets across the board. And so I feel like we definitely are well-positioned to -- just from a capacity perspective.

There's areas on the behavioral side that are probably a bit tighter, areas in the country that are a bit tighter than others. But I still -- even with that, we're performing well under our SLAs. The virtual primary care is really an interesting question. A lot of the virtual primary care that we'll be enabling is -- will be AMG related.

But what we're also doing, I think, rather uniquely is allowing a provider -- or allowing our customers to use their own providers in addressing the virtual primary care needs. And so while that may necessitate us ramping up some, what I think it really will be doing is allowing our customers to utilize their assets a lot more efficiently as they roll out virtual primary care across their footprint. So the mix, I don't really have a number at my fingertips in terms of number of providers as it relates to the various categories. I would tell you, the lion's share -- more than the lion's share is urgent care related.

We certainly have -- but we have adequate capacity across the other specialties, again, to meet the SLAs that we've got.

Jessica Tassan -- Piper Sandler -- Analyst

OK. That's helpful. And I think a really helpful distinction on just the primary care docs or primary care being reliant on customer doctors as opposed to your own. My just last question is, as you guys are rolling out Converge with payers, should we be looking for, for example, like with the LiveHealth Online JV, should we be looking for like a new platform or a new consumer-facing app to support that launch or those several launches? Thanks.

Ido Schoenberg -- Chairman and Chief Executive Officer

Hi, Jessica, that's a great question. So years ago, we -- our brand was very important to us, and we had different apps. And then when we partnered with the like of Anthem at the time, we created LiveHealth Online as a brand. Where all this is going is that our brand really is much less important.

The trusted brand in healthcare are the providers and their partners, and we are offering technology and services to make them what they do best even better. Converge is replacing the technology, it used to be an SDK embedded in dedicated apps in the technology that's called widgets. It basically allows our customers to build their whole branded environment to use digital assets that they already own and still benefit from all the logistics and capabilities of matchmaking services and information that we provide for them without losing an inch on the integrity of their user-facing asset. In general, everything we do is very responsive.

So whether it's an app or a website, whether it's a computer or a tablet, it all works exactly on the same way. And it has the faith that our customers want us to have. So we gratefully took one step backwards, if you will, allowing our customers to take their natural place to the forefront. And in many ways, that's a very welcome change.

If you think about your own family, would you rather get care from Cleveland Clinic or Intermountain or Amwell? Of course, we love Amwell, but we think that your level of trust with the academic medical center or your trusted network in your community is rightfully much stronger and much more robust, and our role is really to empower and enable them, and that is translated into the architecture and the experience that you can see or in many cases, not see on Converge.

Jessica Tassan -- Piper Sandler -- Analyst

Got it. Thank you. That's so helpful.

Operator

Ido, There are no further questions at this time. I'll now turn the call back over to you for closing remarks.

Robert Shepardson -- Chief Financial Officer

I think Ido maybe got dropped. Hold on one moment. Here we go.

Sue Dooley -- Investor Relations

Ido, we're ready for any closing remarks you have.

Ido Schoenberg -- Chairman and Chief Executive Officer

Well, thank you, everyone, for joining us today. As you can see, this is a very exciting quarter in a super exciting year. We can't wait to gear up our sales for Converge into 2023, which is bound to be a very interesting selling year for us. So thank you again for joining us and look forward to talking with you very soon.

Operator

[Operator signoff]

Duration: 0 minutes

Call participants:

Sue Dooley -- Investor Relations

Ido Schoenberg -- Chairman and Chief Executive Officer

Robert Shepardson -- Chief Financial Officer

Charles Rhyee -- Cowen and Company -- Analyst

Jack Wallace -- Guggenheim Partners -- Analyst

Ricky Goldwasser -- Morgan Stanley -- Analyst

Eric Percher -- Nephron Research -- Analyst

Aron Corin -- BTIG -- Analyst

Stan Berenshteyn -- Wells Fargo Securities -- Analyst

Jessica Tassan -- Piper Sandler -- Analyst

More AMWL analysis

All earnings call transcripts